Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study - The Lancet Oncology

$ 23.99

4.8 (413) In stock

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance, Journal of Hematology & Oncology

Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis - Zhonghan Zhang, Kangmei Zeng, Shen Zhao, Yuanyuan Zhao, Xue Hou, Fan Luo, Feiteng

Contemporary Treatment of Metastatic Non-Small Cell Lung Cancer - ppt download

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study - The Lancet Oncology

Cancers, Free Full-Text

Precision treatment for metastatic non–small cell lung cancer: A conceptual overview

Frontiers Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort

Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis

Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know

Frontiers Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer

Frontiers An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance, Journal of Hematology & Oncology